iFCR Phase II Study Looks Promising: My wife, a... - CLL Support

CLL Support

22,474 members38,611 posts

iFCR Phase II Study Looks Promising

ltcbbaker profile image
2 Replies

My wife, a younger, fit, otherwise healthy person diagnosed with CLL (unmutated IGHV, 11q deletion) began a Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR) at Dana Farber in Boston. She just completed 1st month of treatment with remarkable results showing no side affects. WBC down from 50,000 to 6,000, "walnut sized" lymph nodes in neck now undetectable, "lime sized" nodes in abdomen that distended stomach "looking pregnant" reduced to point where her stomach is now flat. We begin 2nd of six monthly 3-day FCR infusions in two days, Ibrutinib pill continues daily for 8-month trial duration. We are optimistic that she will meet goal of trial, MRD negativity 2-months post treatment. She is sharing her treatment experience via webcast on Patient Power web site: patientpower.eu/videos/lead...

Written by
ltcbbaker profile image
ltcbbaker
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Justasheet1 profile image
Justasheet1

Itcbbaker,

I'm so glad she is responding well to tx. Giving her cyber hugs and keep us updated on her progress.

Jeff

Dinasantos profile image
Dinasantos

Hi Itcbbaker,

I am so glad to hear that she is doing well. Was she offered the other trial ipi-145?

What made her decide to go with FCR/ibrutinib?

Was she told she only had to take the ibrutinib for 8 months or is it "lifetime" as long as you can tolerate it?

Best regards/God's speed to her and your family :)

You may also like...

Anyone attend Mayo clinic phase II trial of EGCG on CLL?

clinic phase II trial of EGCG on CLL patients. However, the trial finished in 6 months, so we do...

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

CD20) in combination with ibrutinib (Imbruvica) for the treatment of patients with chronic...

Fixed Duration A & O Phase 2 Study...anyone?

never need treatment, but I guess it's not the case. I really want to get my 1st treatment right,...

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

lines of treatment 4), the ORR with pirtobrutinib was 62% . The ORR was similar in CLL patients...

Breaking news form ASH conference: looks like Ibrutinib May be better than FCR for some patients

Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic...